Summary of results K: Relief of phonophobia within two hours in placebo‐controlled studies | |||||||||
Route of administration | Dose (mg) | Number of | Number with outcome/total | Percent with outcome | Relative benefit (95% CI) | NNT (95% CI) | |||
Studies | Participants | Active | Placebo | Active | Placebo | ||||
In participants with moderate or severe baseline pain | |||||||||
Oral | 50 | 4 | 852 | 244/490 | 134/362 | 50 | 37 | 1.4 (1.2 to 1.6) | 7.8 (5.1 to 16) |
Oral | 100 | 7 | 2118 | 736/1492 | 164/626 | 49 | 26 | 1.8 (1.6 to 2.1) | 4.3 (3.7 to 5.3) |
Subcutaneous | 6 | 3 | 572 | 223/310 | 101/262 | 72 | 39 | 1.8 (1.5 to 2.2) | 3.0 (2.4 to 3.9) |
Intranasal | 20 | 3 | 933 | 309/594 | 93/339 | 52 | 27 | 1.9 (1.6 to 2.3) | 4.1 (3.3 to 5.4) |
In participants with mild baseline pain | |||||||||
Oral | 50 | 3 | 413 | 105/202 | 37/211 | 52 | 18 | 3.0 (2.2 to 4.2) | 2.9 (2.3 to 3.9) |
Oral | 100 | 3 | 400 | 120/189 | 37/211 | 63 | 18 | 3.7 (2.7 to 5.1) | 2.2 (1.8 to 2.7) |